{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:19:03Z","timestamp":1784125143495,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010648","name":"Universitaire Ziekenhuizen Leuven, KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.radonc.2025.110836","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:38:21Z","timestamp":1741261101000},"page":"110836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial"],"prefix":"10.1016","volume":"206","author":[{"given":"A","family":"De Caluw\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1126-086X","authenticated-orcid":false,"given":"S.","family":"Bellal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-1821","authenticated-orcid":false,"given":"K.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Peignaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Remouchamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7104-7808","authenticated-orcid":false,"given":"A.","family":"Baten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Longton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bessieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vu-Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.Van","family":"Gestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4493-3748","authenticated-orcid":false,"given":"M.","family":"Ignatiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-5545","authenticated-orcid":false,"given":"E.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Buisseret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vandekerkhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6805-8802","authenticated-orcid":false,"given":"A.","family":"Gulyban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7400-2293","authenticated-orcid":false,"given":"P.","family":"Poortmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110836_b0005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.radonc.2025.110836_b0010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.radonc.2025.110836_b0015","article-title":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer. JAMA","volume":"60637","author":"Nanda","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.radonc.2025.110836_b0020","doi-asserted-by":"crossref","unstructured":"F. Cardoso A. Bardia F. Andre D.W. Cescon H.L. McArthur M.L. Telli et al. KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative (ER+\/HER2\u2212) breast cancer Https:\/\/DoiOrg\/101200\/JCO20193715_supplTPS601 37 2019 TPS601 \u2013TPS601 10.1200\/JCO.2019.37.15_SUPPL.TPS601.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS601"},{"key":"10.1016\/j.radonc.2025.110836_b0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.110836_b0030","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.radonc.2025.110836_b0040","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1245\/s10434-022-11666-2","article-title":"Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer","volume":"29","author":"Whitworth","year":"2022","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0045","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes","volume":"13","author":"Onkar","year":"2023","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.radonc.2025.110836_b0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0060","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257452","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/PD-l1 expression are linked in breast cancer","volume":"6","author":"Buisseret","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2025.110836_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-023-00508-3","article-title":"Immunotherapy in breast cancer: an overview of current strategies and perspectives","volume":"9","author":"Debien","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.radonc.2025.110836_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20138-8","article-title":"Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells","volume":"11","author":"G\u00f3mez-Aleza","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110836_b0075","doi-asserted-by":"crossref","DOI":"10.1007\/s12609-023-00507-0","article-title":"Pre-operative Radiation and Immunotherapy in the Treatment of Non-metastatic Breast Cancer","author":"Karukonda","year":"2023","journal-title":"Current Breast Cancer Reports"},{"key":"10.1016\/j.radonc.2025.110836_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.semradonc.2022.01.001","article-title":"Immunotherapy Combined with Radiation Therapy in Breast Cancer: A Rapidly Evolving Landscape","author":"Santa-Maria","year":"2022","journal-title":"Seminars in Radiation Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0085","article-title":"Determinants of radiation dose to immune cells during breast radiotherapy","author":"Loap","year":"2024","journal-title":"Strahlentherapie und Onkologie"},{"key":"10.1016\/j.radonc.2025.110836_b0090","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2017.05.029","article-title":"Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer","volume":"99","author":"Hu","year":"2017","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110836_b0095","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110836_b0100","article-title":"Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose? J Immunother","volume":"9","author":"Demaria","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.110836_b0105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08601-1","article-title":"Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial","volume":"21","author":"De Caluw\u00e9","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110836_b0115","article-title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial","volume":"14","author":"Buisseret","year":"2023","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110836_b0120","doi-asserted-by":"crossref","first-page":"P378","DOI":"10.1186\/2051-1426-3-S2-P378","article-title":"Adenosine regulates radiation therapy-induced anti-tumor immunity","volume":"3","author":"Wennerberg","year":"2015","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110836_b0125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicology and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"American Journal of Clinical Oncology: Cancer Clinical Trials"},{"key":"10.1016\/j.radonc.2025.110836_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007279","article-title":"First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial","volume":"11","author":"De Caluwe","year":"2023","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.radonc.2025.110836_b0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2014.11.030","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer","volume":"114","author":"Offersen","year":"2015","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.radonc.2015.12.027","article-title":"ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1","volume":"118","author":"Offersen","year":"2016","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110836_b0150","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ijrobp.2011.09.054","article-title":"Standardizing naming conventions in radiation oncology","volume":"83","author":"Santanam","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110836_b0155","unstructured":"ICRU. ICRU Report No. 91. J ICRU 2017;14."},{"key":"10.1016\/j.radonc.2025.110836_b0160","doi-asserted-by":"crossref","unstructured":"Weichselbaum R, Lynch C, Pitroda SP, Weichselbaum RR. Review Radiotherapy, immunity, and immune checkpoint inhibitors. vol. 25. 2024.","DOI":"10.1016\/S1470-2045(24)00075-5"},{"key":"10.1016\/j.radonc.2025.110836_b0165","first-page":"1","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","author":"Altorki","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nature Communications"},{"key":"10.1016\/j.radonc.2025.110836_b0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00003","article-title":"PEARL: A Phase Ib\/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer","author":"Ho","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0180","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ijrobp.2012.10.034","article-title":"Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer","volume":"85","author":"Bondiau","year":"2013","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110836_b0185","doi-asserted-by":"crossref","unstructured":"Y. Ji G. Liao N. Luo Y. Jiang X. Liao W. Tang et al. Abstract P3-04-08: Comparison Of Cone Beam Breast CT And Breast MRI In Preoperative Assessment Of Primary Breast Cancer Tumor Size Cancer Research 83 2023 P3 \u201304-08-P3-04\u20138 10.1158\/1538-7445.SABCS22-P3-04-08.","DOI":"10.1158\/1538-7445.SABCS22-P3-04-08"},{"key":"10.1016\/j.radonc.2025.110836_b0190","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0284185114524089","article-title":"Magnetic resonance imaging of breast cancer: factors affecting the accuracy of preoperative lesion sizing","volume":"56","author":"Mennella","year":"2015","journal-title":"Acta Radiologica"},{"key":"10.1016\/j.radonc.2025.110836_b0195","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ijrobp.2019.12.037","article-title":"Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial","volume":"106","author":"Bosma","year":"2020","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110836_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.09.024","article-title":"Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial","author":"Thomsen","year":"2022","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0205","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-024-02497-4","article-title":"Advances in breast cancer treatment: a systematic review of preoperative stereotactic body radiotherapy (SBRT) for breast cancer","volume":"19","author":"Bilski","year":"2024","journal-title":"Radiation Oncology"},{"key":"10.1016\/j.radonc.2025.110836_b0210","first-page":"94","article-title":"Preoperative robotic radiosurgery for early breast cancer: Results of the phase II ROCK trial (NCT03520894)","volume":"37","author":"Meattini","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.110836_b0215","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ijrobp.2019.11.406","article-title":"Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation","volume":"106","author":"Vasmel","year":"2020","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.radonc.2025.110836_b0220","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2021.10.005","article-title":"Unintended dose to the lower axilla in adjuvant radiotherapy for breast cancer: differences between tangential beam and VMAT","volume":"164","author":"Imane","year":"2021","journal-title":"Radiotherapy and Oncology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:44:25Z","timestamp":1777553065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":44,"alternative-id":["S0167814025001318"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110836","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adapting radiation therapy to immunotherapy: Delineation and treatment planning of pre-operative immune-modulating breast iSBRT in 151 patients treated in the randomized phase II Neo-CheckRay trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110836"}}